Simona Corso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4822451/publications.pdf

Version: 2024-02-01

46 papers	4,432 citations	159585 30 h-index	233421 45 g-index
47 all docs	47 docs citations	47 times ranked	6680 citing authors

#	Article	IF	Citations
1	A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Translational Oncology, 2022, 15, 101260.	3.7	3
2	hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of â€˜MET-addictedâ€™ cancers. Journal of Experimental and Clinical Cancer Research, 2022, 41, 112.	8.6	5
3	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
4	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	5.3	6
5	Microsatellite instability in Gastric Cancer: Between lights and shadows. Cancer Treatment Reviews, 2021, 95, 102175.	7.7	88
6	Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers, 2021, 13, 4094.	3.7	10
7	Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells. Cancers, 2020, 12, 2218.	3.7	10
8	Patient-Derived Cancer Models. Cancers, 2020, 12, 3779.	3.7	9
9	Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review. Updates in Surgery, 2020, 72, 951-966.	2.0	14
10	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cellâ€“Intrinsic Transcriptional MSI Traits. Cancer Research, 2019, 79, 5884-5896.	0.9	53
11	The landscape of d16HER2 splice variant expression across HER2-positive cancers. Scientific Reports, 2019, 9, 3545.	3.3	22
12	Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts. Neoplasia, 2018, 20, 443-455.	5.3	17
13	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. Clinical Cancer Research, 2018, 24, 1082-1089.	7.0	76
14	Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metabolism, 2018, 28, 848-865.e6.	16.2	184
15	Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 67-87.	0.1	0
16	YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC. Neoplasia, 2017, 19, 1012-1021.	5.3	77
17	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. Oncogene, 2017, 36, 1200-1210.	5.9	28
18	Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget, 2017, 8, 57654-57669.	1.8	99

#	Article	IF	Citations
19	How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. Trends in Molecular Medicine, 2016, 22, 534-544.	6.7	50
20	Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget, 2015, 6, 5182-5194.	1.8	72
21	Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Molecular Oncology, 2014, 8, 1561-1574.	4.6	15
22	Targeted therapies in cancer and mechanisms of resistance. Journal of Molecular Medicine, 2014, 92, 677-679.	3.9	6
23	EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1327-1335.	2.5	43
24	Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
25	Cell-Autonomous and Nonâ€“Cell-Autonomous Mechanisms of HGF/METâ€“Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective. Cancer Discovery, 2013, 3, 978-992.	9.4	84
26	Enhanced c-Met activity promotes G-CSFâ€“induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood, 2011, 117, 419-428.	1.4	114
27	The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth. Journal of Biological Chemistry, 2010, 285, 38756-38764.	3.4	46
28	MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors. Cancer Research, 2010, 70, 7580-7590.	0.9	164
29	Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Molecular Cancer, 2010, 9, 121.	19.2	95
30	Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction. Science Signaling, 2009, 2, ra80.	3.6	84
31	A Correction to the Research Article Titled: "Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction" by A. Bertotti, M. F. Burbridge, S. Gastaldi, F. Galimi, D. Torti, E. Medico, S. Giordano, S. Corso, G. Rolland-Valognes, B. P. Lockhart, J. A. Hickman, P. M. Comoglio, L. Trusolino. Science Signaling, 2009, 2, er11.	3.6	23
32	Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene, 2008, 27, 684-693.	5.9	126
33	Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. Journal of Experimental Medicine, 2008, 205, 1673-1685.	8.5	233
34	Semaphorin 4D regulates gonadotropin hormoneâ€releasing hormone-1 neuronal migration through PlexinB1â€Met complex. Journal of Cell Biology, 2008, 183, 555-566.	5.2	92
35	MicroRNAs Impair MET-Mediated Invasive Growth. Cancer Research, 2008, 68, 10128-10136.	0.9	168
36	Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene, 2007, 26, 6968-6978.	5.9	131

#	Article	IF	Citations
37	Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS). Oncogene, 2006, 25, 3689-3698.	5.9	125
38	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Research, 2006, 66, 4750-4757.	0.9	123
39	Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood, 2005, 105, 4321-4329.	1.4	226
40	HGF/MET signalling protects Plasmodium-infected host cells from apoptosis. Cellular Microbiology, 2005, 7, 603-609.	2.1	100
41	p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. Journal of Cell Science, 2005, 118, 4689-4700.	2.0	90
42	Cancer therapy: can the challenge be MET?. Trends in Molecular Medicine, 2005, 11, 284-292.	6.7	218
43	Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene, 2004, 23, 5131-5137.	5.9	164
44	ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. British Journal of Cancer, 2003, 88, 396-400.	6.4	19
45	Hepatocyte growth factor and its receptor are required for malaria infection. Nature Medicine, 2003, 9, 1363-1369.	30.7	133
46	The Semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biology, 2002, 4, 720-724.	10.3	391